Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Septerna, Inc.. The associated price target remains the same with $26.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ram Selvaraju has given his Buy rating due to a combination of factors, primarily focusing on Septerna, Inc.’s recent advancements in their clinical-stage development. The initiation of dosing in the Phase 1 trial of SEP-631 marks a significant milestone for the company, as it returns to clinical-stage status. This trial, which targets chronic spontaneous urticaria and other mast cell-driven diseases, is expected to provide valuable insights into the safety and efficacy of SEP-631, potentially positioning it as a differentiated treatment option.
Furthermore, Septerna is progressing with its parathyroid hormone 1 receptor agonist program, which aims to offer full-day calcium control for hypoparathyroidism patients. The company’s strategic focus on high-value indications, such as CSU, and the potential for SEP-631 to achieve blockbuster status if it can match the efficacy of existing treatments like Xolair, further substantiates the Buy rating. Additionally, Septerna’s ongoing efforts in advancing other programs, including those in partnership with Novo Nordisk, highlight its robust pipeline and potential for future growth.